MX2014006182A - Un metodo para pronosticar reactividad a un tratamiento con un inhibidor de egfr. - Google Patents
Un metodo para pronosticar reactividad a un tratamiento con un inhibidor de egfr.Info
- Publication number
- MX2014006182A MX2014006182A MX2014006182A MX2014006182A MX2014006182A MX 2014006182 A MX2014006182 A MX 2014006182A MX 2014006182 A MX2014006182 A MX 2014006182A MX 2014006182 A MX2014006182 A MX 2014006182A MX 2014006182 A MX2014006182 A MX 2014006182A
- Authority
- MX
- Mexico
- Prior art keywords
- egfr inhibitor
- treatment
- patient
- predicting responsiveness
- egfr
- Prior art date
Links
- 229940121647 egfr inhibitor Drugs 0.000 title abstract 3
- 230000004043 responsiveness Effects 0.000 title 1
- 102000001301 EGF receptor Human genes 0.000 abstract 2
- 108060006698 EGF receptor Proteins 0.000 abstract 2
- 108091070395 Homo sapiens miR-31 stem-loop Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11306568 | 2011-11-25 | ||
| EP12306042 | 2012-08-31 | ||
| PCT/EP2012/073535 WO2013076282A1 (en) | 2011-11-25 | 2012-11-23 | A method for predicting responsiveness to a treatment with an egfr inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2014006182A true MX2014006182A (es) | 2014-12-08 |
Family
ID=47297187
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014006182A MX2014006182A (es) | 2011-11-25 | 2012-11-23 | Un metodo para pronosticar reactividad a un tratamiento con un inhibidor de egfr. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10400284B2 (enExample) |
| EP (1) | EP2783017B1 (enExample) |
| JP (1) | JP6342329B2 (enExample) |
| KR (1) | KR20140104419A (enExample) |
| CN (1) | CN104160038B (enExample) |
| AU (1) | AU2012342397B2 (enExample) |
| BR (1) | BR112014012495A2 (enExample) |
| CA (1) | CA2856594A1 (enExample) |
| MX (1) | MX2014006182A (enExample) |
| WO (1) | WO2013076282A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2931176A1 (en) * | 2013-11-26 | 2015-06-04 | Integragen | A method for predicting responsiveness to a treatment with an egfr inhibitor |
| KR101622454B1 (ko) | 2014-03-04 | 2016-05-18 | 연세대학교 산학협력단 | Egfr 티로신 키나아제 억제제에 대한 항암 치료 반응 예측 마커 |
| WO2015160868A1 (en) * | 2014-04-16 | 2015-10-22 | Signal Pharmaceuticals, Llc | Methods for treating cancer using tor kinase inhibitor combination therapy |
| EP3000895A1 (en) * | 2014-09-26 | 2016-03-30 | Integragen | A method for predicting responsiveness to a treatment with an EGFR inhibitor |
| WO2017014694A1 (en) * | 2015-07-23 | 2017-01-26 | National University Of Singapore | Wbp2 as a co-prognostic factor with her2 for stratification of patients for treatment |
| WO2017187937A1 (ja) * | 2016-04-28 | 2017-11-02 | デンカ株式会社 | 上皮性細胞成長因子受容体阻害剤に対する癌細胞の耐性を判定する方法 |
| CN115943306A (zh) * | 2019-03-29 | 2023-04-07 | 乐天医药生技股份有限公司 | 用于光免疫疗法的方法和相关生物标志物 |
| KR102251864B1 (ko) * | 2019-10-18 | 2021-05-14 | 지니너스 주식회사 | miR-320c를 유효성분으로 포함하는 백금계 항암제에 대한 삼중음성유방암 환자의 약물 반응성 예측용 바이오마커 조성물 |
| CN111798918A (zh) * | 2020-05-28 | 2020-10-20 | 中山大学孙逸仙纪念医院 | 一种免疫治疗疗效预测的血肿瘤突变算法及其构建方法 |
| CN111863159B (zh) * | 2020-06-01 | 2022-02-25 | 中山大学孙逸仙纪念医院 | 一种肿瘤免疫治疗疗效预测的列线图模型的建立方法 |
| JP2025507824A (ja) * | 2022-03-01 | 2025-03-21 | クラウン バイオサイエンス （スーチョウ） インコーポレイテッド | がん患者におけるセツキシマブ感受性を決定するための方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002070751A1 (en) | 2001-03-02 | 2002-09-12 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Pcr method |
| WO2009055343A2 (en) * | 2007-10-22 | 2009-04-30 | Schering Corporation | Fully human anti-vegf antibodies and methods of using |
| WO2009080437A1 (en) * | 2007-12-21 | 2009-07-02 | Exiqon A/S | Micro-rna based drug resistance analysis method |
| WO2010015538A2 (en) * | 2008-08-05 | 2010-02-11 | F. Hoffmann-La Roche Ag | Predictive marker for egfr inhibitor treatment |
| EP2419522A4 (en) | 2009-04-17 | 2012-10-31 | Glen Weiss | METHOD AND KITS FOR THE FORECASTING OF THERAPY RESULTS OF TYROSINE CHINESE INHIBITORS |
| AU2010324529A1 (en) * | 2009-11-24 | 2012-07-19 | The University Of Western Australia | Modulation of epidermal growth factor receptor ligands |
| WO2011135459A2 (en) * | 2010-04-29 | 2011-11-03 | Medical Prognosis Institute A/S | Methods and devices for predicting treatment efficacy |
-
2012
- 2012-11-23 JP JP2014542865A patent/JP6342329B2/ja not_active Expired - Fee Related
- 2012-11-23 BR BR112014012495A patent/BR112014012495A2/pt active Search and Examination
- 2012-11-23 AU AU2012342397A patent/AU2012342397B2/en not_active Ceased
- 2012-11-23 CA CA2856594A patent/CA2856594A1/en not_active Abandoned
- 2012-11-23 WO PCT/EP2012/073535 patent/WO2013076282A1/en not_active Ceased
- 2012-11-23 EP EP12797814.6A patent/EP2783017B1/en not_active Not-in-force
- 2012-11-23 MX MX2014006182A patent/MX2014006182A/es unknown
- 2012-11-23 CN CN201280067832.4A patent/CN104160038B/zh not_active Expired - Fee Related
- 2012-11-23 US US14/360,311 patent/US10400284B2/en not_active Expired - Fee Related
- 2012-11-23 KR KR1020147014013A patent/KR20140104419A/ko not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| BR112014012495A2 (pt) | 2017-06-06 |
| JP6342329B2 (ja) | 2018-06-13 |
| EP2783017B1 (en) | 2018-12-26 |
| US10400284B2 (en) | 2019-09-03 |
| JP2014533960A (ja) | 2014-12-18 |
| CN104160038A (zh) | 2014-11-19 |
| KR20140104419A (ko) | 2014-08-28 |
| AU2012342397A1 (en) | 2014-06-12 |
| WO2013076282A1 (en) | 2013-05-30 |
| CA2856594A1 (en) | 2013-05-30 |
| AU2012342397B2 (en) | 2018-04-05 |
| US20140370029A1 (en) | 2014-12-18 |
| EP2783017A1 (en) | 2014-10-01 |
| CN104160038B (zh) | 2018-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2014006182A (es) | Un metodo para pronosticar reactividad a un tratamiento con un inhibidor de egfr. | |
| MX2014000292A (es) | Usos de inhibidores etiquetados hsp90. | |
| LTPA2019503I1 (lt) | Modifikuotų T ląstelių, turinčių chimerinų antigeno receptorių, panaudojimas vėžio gydymui | |
| IL233019A0 (en) | System and method for locating sources of biological arrhythmias | |
| EP2770090A4 (en) | METHOD FOR PRODUCING A NUCLEIC ACID LIBRARY AND USES THEREOF AND KITS THEREFOR | |
| IN2012DN02485A (enExample) | ||
| PT2683384E (pt) | Métodos de tratamento de cancro utilizando 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidina-2,6-diona | |
| MX358541B (es) | Metodos para predecir el riesgo de desarrollar hipertension. | |
| WO2012106718A3 (en) | Methods of using gene expression signatures to select a method of treatment, predict prognosis, survival, and/or predict response to treatment | |
| IL229114B (en) | Methods for predicting response to cancer treatment using servalon as a predictor | |
| EP2788773A4 (en) | DEVICE, SYSTEM AND METHOD FOR IDENTIFYING CIRCULATING TUMOR CELLS | |
| WO2011146568A8 (en) | Predicting response to a her inhibitor | |
| WO2013040436A3 (en) | Esx-mediated transcription modulators and related methods | |
| EP2911056A4 (en) | METHOD FOR RESTRICTING THE CONSUMPTION OF A STORAGE SYSTEM AND MEMORY CONTROL | |
| EA201590773A1 (ru) | Способ диагностики для прогнозирования ответа на ингибитор фактора некроза опухоли альфа (tnf альфа) | |
| MX348655B (es) | Biomarcadores para pronosticar sensibilidad a tratamientos contra el cancer. | |
| MX354270B (es) | Uso de un anticuerpo antiesclerostina en el tratamiento de la pérdida ósea alveolar. . | |
| PH12013502530A1 (en) | Glioblastoma inhibiting compounds and their use | |
| EP2568459A4 (en) | TRAFFIC CONTROL SYSTEM AND METHOD | |
| IL232493A0 (en) | A method for quantifying cancer treatment | |
| PL2678443T3 (pl) | Sposób ilościowego określania ludzkiego DNA przy użyciu kontroli wewnętrznej | |
| MX2013008069A (es) | Inhibidor del factor de celulas madre. | |
| MX2016006782A (es) | Un metodo para predecir la capacidad de respuesta a un tratamiento con un inhibidor del egfr. | |
| GB201207722D0 (en) | Method | |
| EP2530468A4 (en) | ASSAY PROCEDURE FOR HUMAN SCD14-ST |